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During the past several years groups of myeloma proteins that bind specific haptens have
been described (1-15) and used as model immunoglobulins for studying structure-function
relationships . However, the relatively low affinity expressed by these proteins for their
ligands raised the possibility that such interactions represented only weak cross-reactions,
and that the myeloma proteins may not, in fact, have been derived from precursor cells
which could be stimulated by these ligands . Recent evidence, however, has clearly shown
that such reservations are not warranted . Thus, IgM antibodies raised in mice to
phosphorylcholine (PC)' (16-20), all - 3)dextrans (21), fructosans, and galactans (M .
Potter, R . Lieberman, and B . Mushinski, unpublished observations) possess idiotypic
determinants similar to those present on IgA myeloma proteins with the corresponding
specificity, which suggests that a close structural similarity exists between the myeloma
proteins and antibody molecules . In the PC system, a remarkable uniformity of structural
and functional characteristics has been described on members of a group of PC-binding
myeloma proteins (S63-T15 group) . This group shares idiotypic determinants, the same
amino-terminal sequence of heavy and light chains (6), and indistinguishable binding
characteristics for a number of choline compounds (4) . Two distinct idiotypic determi-
nants have been described, one of which is located in the binding site (22) and the other in
a nonbinding site region (3) . Of particular interest is the idiotypic determinant located in
the binding site (22) since it is associated with anti-PC antibody produced in all inbred
strains of mice tested, regardless of allotype (19) . This correlates with the finding that the
binding specificity of anti-PC antibody from each of these mouse strains is indistinguisha-
ble from that ofT15 (23) . This finding suggests that a particular PC-binding site, but not
necessarily a nonbinding site region, may be conserved in mice (19, 23) . Thus, any
PC-binding myeloma protein with a T15-binding site, but having anon-BALB/c allotype,
becomes relevant as a possible prototype for anti-PC antibody of that particular allotype
group .
* This work was supported in part by grants AI-11635 and CA-16032 from the National Institutes of
Health, by grant IM-29 from the American Cancer Society, Missouri Division and a grant from the
following companies : Brown & Williamson Tobacco Corporation ; Larus and Brother Company, Inc . ;
Liggett & Myers, Incorporated ; Lorillard, a Division of Loews Theatres, Incorporated ; Philip Morris,
Incorporated ; R . J . Reynolds Tobacco Company ; United States Tobacco Company ; and Tobacco
Associates, Inc .
'Abbreviations used in this paper: AC, acetylcholine ; C, choline ; GPC, glycerophosphorylcholine ;
PC, phosphorylcholine ; PnC, pneumococcal C polysaccharide ; PTH, phenylthiohydantoins .
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We report here a PC-binding myeloma protein whose heavy chain carries the
allotypic determinants of the az group (e.g . C57BL/6) . The tumor was induced in
a congenic strain of BALB/c mice (strain CB-20) which carries the C57BL/
ka .IgCH complex locus (24) . This strain was obtained by introgressively
backcrossing the I9CH complex locus of C57BL/ka (denoted by the unassigned 2
allotypic determinant) to BALB/c for 20 consecutive generations and then
making the 20th generation homozygous for the C57BL/ka I9CH 2 determinant
by brother-sister mating . Plasmacytoma CBPC 2, induced in one of these CB-20
mice, produces an IgA protein which carries the C57BL/ka allotype and shows
certain structural and functional characteristics, particularly in the combining
region, which are similar to those of the S63-T15 group . In addition, this
myeloma protein possesses the site-associated idiotypic determinant, but, like
the induced C57BL/6 anti-PC antibody, it does not carry the nonbinding site
determinant .
Materials and Methods
Source of Tumors .
￿
Theorigins of the plasmacytomas TEPC 15, HOPC 8,MOPC 167, McPC 603,
andMOPC 511that produce the PC-binding myeloma proteins T15, H8, M167, M603, and M511 (all
IgA, x) have been described in detail elsewhere (3) . The plasmacytoma CBPC 2 was induced in a
CB-20 mouse that had been injected intraperitoneally with 0.5 ml of2,6,10,14-tetramethylpentadec-
ane (Pristane ; Aldrich Chem . Co ., Inc., Milwaukee, Wis.) and then 40 days laterwith Abelson Virus
(MLV-A) (25) . This plasmacytoma produced an IgA (a, x) myeloma protein that precipitated the
PC-containing LB-4 antigen of Lactobacillus acidophilus .
Purification of Myeloma Proteins .
￿
The PC-binding myeloma proteins were purified by affinity
chromatography from a PC-Sepharose immunoadsorbent column (26) . The isolated proteins were
shown to be pure by immunodiffusion with class- and type-specific antisera prepared in rabbits .
Amino-terminal Sequence Determination .
￿
Heavy and light chains were separated on Sephadex
G100 columns in 6 M urea, 1 M acetic acid after partial reduction and alkylation as previously
described (27) . Amino-terminal sequence analysis was performed on a Beckman 890 C sequencer
(Beckman Instruments, Inc., Spinco Div., Palo Alto, Calif.) using the standard dimethylallylamine
program . Thiazolinone derivatives obtained after each degradation cycle were converted to
phenyltbiohydantoins (PTH) as previously described (13) . PTH amino acids were identified by gas
chromatography on SP400 columns (28) and/or by amino acid analysis after hydrolysis in hydriodic
acid (29) .
Measurement of Binding Specificity .
￿
Pneumococcal C polysaccharide (PnC) was isolated from
Diplococcus pneumoniae strain R36A according to the procedure of Liu and Gotschlich (30) .
Tyramine was introduced into PnC (31), and the tyraminyl carbohydrate was iodinated with "'Iby
the chloramine T method (32) . Inhibition of precipitation (4) between ['z5I]PnC and the myeloma
proteins byPC and three of its analogues, glycerophosphorylcholine (GPC), acetylcholine (AC), and
choline (C), was used to determine the binding specificity of this protein . All reactions were carried
out at equivalence in 0.15M NaCl buffered with 0.005M phosphate(PBS) . 0.2 ml of a serum dilution
containing the myeloma protein was incubated with 0.1 ml of various concentrations of the choline
analogues . After 30 min at 24°C, 0.1 ml of PBS containing 100 jug (34,000 cpm) of [`I]PnC was
added. The reaction mixture was incubated for 16-18h at 4°C and the precipitate washed four times
inPBS; theamount of radioactive precipitatewasdetermined in agammacounter .
Isoelectric Focusing in Polyacrylamide Gels .
￿
Purified myeloma proteins were fully reducedwith
0.2M 2-mercaptoethanol in 7M guanidine, 0.5M Tris-HCI, pH 8.6 (2 h, 22°C) andalkylated with 0.4
M iodoacetamide (45 min, 4°C) (33) . A portion of each sample was dialyzed against 6M urea and
stored at -20°C. The major portion of the sample was separated into heavy and light chains by
Sephadex G100 chromatography in 1M propionic acid, 4.5M urea . Isolated heavy and light chains
were dialyzed against 6 M urea and stored at -20°C.
Isoelectric focusing in thin layer polyacrylamide gel slabs was performed at 4°C in the apparatus
described by Reid and Bieleski (34) . The gelwas composed of 5% acrylamide (Bio Rad Laboratories,610
￿
PHOSPHORYLCHOLINE-BINDING IgA MYELOMA PROTEIN
Richmond, Calif.), 2% ampholytes (Ampholines, LKB Instruments, Inc., Rockville, Md.), pH range
5.0 to 9.5, and 6 M urea (Ultrapure grade; Schwarz/Mann Div., Becton, Dickinson & Co.,
Orangeburg, N.Y.) . Phosphoric acid, 0.5% was used for the anode solution (upper trough) and
ethanolamine, 0.8%, for the cathode solution (lower trough) . Samples were focused for 12-14 h at a
constant current of 2.5 mA and then for an additional hour at 800-900V. Gels were fixed in asolution
of 5% trichloroacetic acid and5% sulfosalicylic acid for4h, washed repeatedly in 40% ethanol, andair
dried. Protein bands were detected by staining the dried gels for 4-12 h with 0.025% Coomassie
brilliant blue dissolved in 40% ethanol.
Idiotypic Antisera .
￿
The preparation and characterization of two idiotypic antisera which react
with T15 and H8 are described in detail elsewhere (19, 20, 22). One antiserum, prepared in rabbits to
H8, was passed over an H8-Sepharose immunoadsorbent and antibodies with specificity for the
binding site were isolated by elution with PC. This antibody preparation, designated R2 anti-H8
was idiotypically specific forH8 and T15, andthis reaction was greater than 98% hapten inhibitable
(22). Another antiserum to H8 was prepared in AM mice (19, 20) and made idiotypically specific by
adsorption to Sepharose coupledwith M460 (9 mg/ml) in BALB/c serum. Though this antiserumwas
also idiotypically specific, it was directed primarilyto determinant(s) not directly associated with the
combining site (22).
Detection of Idiotypic Determinants .
￿
The hemagglutination-inhibition (HI) test was performed
as previously described (19, 20). Purified myeloma proteins were tested fortheirability to inhibitthe
agglutination of T15-coated sheep erythrocytes (SRBC) (35) by a limiting dilution of idiotypic
antiserum. The inhibition endpoint was the highest dilution of inhibitor which gave no visible
hemagglutination.
Quantitative measurements of an idiotypic specificity were determined by solid phase radioim-
munoassay (TBA) which has been previously described (22) . Micro-test tubes (Beckman Instru-
ments, Inc., Fullerton, Calif.) coated with idiotypic antibodies were incubated with ^-0.5 ng/ml of
[111I]HS (6,000 cpm) (32) in the presence of various amounts of different myeloma proteins. The
bound radioactivitywas measured in a gammacounter andthe percent inhibition of specific binding
was determined. Specific and nonspecific binding to antibody-coated tubes was 33% and 4%,
respectively, of added cpm.
Results
Allotypic Specificity of CBPC 2. BALB/c IgA immunoglobulins carry the
A12.
13 . 14 determinants (24), whereas those of C57BL/ka carry the A15 determi-
nant. As shown by the immunodiffusion pattern in Fig. 1, CBPC 2 protein was A15
which indicates that the heavy chain constant regions of this protein were of
C57BL/ka origin . The origin of the light chains is undetermined since K chain
allotypes are not known in the mouse.
Amino-terminal Sequence Analysis . The results of partial amino acid se-
quences of both the light and heavy chains of CBPC 2 are shown in Table I and
compared with those of H8, T15, and M603. As indicated previously, H8 and T15
have identical sequences through the first hypervariable region of both their
heavy and light chains (6) and appear on the basis of these and other data (3, 20,
22) to be identical molecules. The heavy chain of M603 is identical to T15
through the first hypervariable region but its light chain differs by 18 out of 41
residues, including eight in the hypervariable region (27) . CBPC 2 shows a
striking sequence similarity to T15. No differences are seen in the light chains
through position 36 and only two changes occur in the first 36 residues of the
heavy chain, both of which are outside the hypervariable region .
Isoelectric Focusing Pattern of Light Chains. An additional measure of
structural similarity among proteins is the isoelectric point (pI) . Therefore, the
heavy and light chains of T15, CBPC 2, and other PC-binding proteins were
analyzed by isoelectric focusing . Preliminary experiments indicated that clearJ . L. CLAFLIN, S . RUDIKOFF, M. POTTER, AND J. M . DAVIE
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distinctions among myeloma proteins could be made if fully reduced, ratherthan
mildly reduced, proteins were analyzed . Light chains typically gave from one to
four bands after mild reduction depending on the protein, but yielded three to
four bands after complete reduction (36) . The isoelectric spectra of light and
heavy chains of CBPC 2, T15, H8, M603, M511, M167, and of M460, a
DNP-binding IgA myeloma protein, are shown in Fig. 2 . The light chains focused
in restricted regions over a broad range in pH, 5.5 to 8.0 . As can be clearly seen,
T15 andH8 light chains, as anticipated, but also CBPC 2 light chains, focus with
identical pI's . In addition, M511 and M167 light chains, which differ by only a
single amino acid in their amino-terminal regions (37), focus similarly . That
isoelectric focusing can readily reveal compositional differences as well as
similarities is demonstrated by the light chain patterns obtained with T15,
M603, M167, and M460 proteins, which belong to entirely different subgroups
(6) . Thus, the data indicate that other portions of the CBPC 2 light chain, in
addition to the amino-terminal regions, are similar to those ofT15.
Unlike -y-chains (38), the a-chains, after either full or mild reduction, entered
the gel poorly and, even then, were not readily resolved into distinct bands . This
may relate to the higher carbohydrate level in IgA and the lability of sialic acid
residues .
Binding Specificity of CBPC2.
￿
Measurement ofthe relative binding specific-
ity of the PC-binding myeloma proteins was used as a criterion for comparison of
their combining sites. As shown by other laboratories as well as our own (4, 18),
each of the proteins, T15 (H8), M603, M167, and M511, binds PC, but their
FiG . 1 . Identification of allotypic determinants on CBPC 2 . Upper: Ouchterlony plate
showing interaction of AL/N anti-BALB/c IgA myeloma protein X44(anti-A'~ with CBPC 2
(2) and T15 (15) . The precipitin line formed with the T15 is partially inhibitedby the CBPC 2
myeloma protein indicating some shared allotypic specificities between C57BL and BALB/c
IgA myeloma proteins . The strong precipitin line with T15 and not CBPC 2 indicates the
presence of BALB/c IgA allotype A'2 on T15 and its absence on CBPC 2 . Lower: BALB/c
anti-IgA myeloma protein M320 (anti-A'") . M320 was produced by a plasmacytoma induced
in a backcross-6 mouse during development of the CB-20 congenic strain and possesses the
C57BL/ka IgC alpha chain . The antiserum showsthe presence of the C57BLIgA allotype on
CBPC 2and its absenceon T15.612
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vL
T15 (H8) * Asp Ileu Val MetThrGln Ser ProThrPheLeu AlaValThr Ala Ser Lys Lys Val Thr
CBPC 2
M603*
￿
Ser Ser -Ser-Ser -Gly GluArg
VH
TABLE I
Amino-terminal Sequences of Myeloma
5
￿
10
￿
15
￿
20
T15(H8)* Glu ValLysLeu ValGlu Ser GlyGlyGlyLeu ValGlnProGly GlySerLeuArgLeu
CBPC 2
￿
Ser- Arg
M603*
* Sequences determined by Barstad et al . (6) and by Rudikoff and Potter (27) .
FIG. 2. Isoelectric spectra of heavy and light chains of PC-binding myeloma proteins .
Reduced and alkylated proteins and isolated light chains were focused in a thin layer
polyacrylamide gel in pH 5 to 9.5 ampholytes . With the exception of the major dark band at
pH 5.9 in M167, the multiple bandingappearing at pH 6.0 t 0.2 in M167, M603, T15, andH8
is due to an unidentified, low molecular weight contaminant.
combining sites display readily distinguishable fine specificity differences .
Comparative analysis of binding characteristics for CBPC 2 and 3 of the 4
different PC-binding proteins are shown in Fig . 3 and Table II . It is readily
apparent that the combining site of CBPC 2 is markedly similar to that of T15 .
Though differing slightly in relative affinity for each of the choline analogues (a
factwhich is most likely due to a variation in immunoglobulin concentration [4]),
they each possessed virtually the same relative specificity for the choline
analogues .J. L. CLAFLIN, S. RUDIKOFF, M. POTTER, AND J. M. DAVIE
Proteins that Bind Phosphorylchollne
25
￿
30
￿
32 35
a b c d e f
Ileu Ser Cys Thr Ala Ser Glx Ser Leu Tyr Ser Ser Lys His LysVal His Tyr Leu Ala Trp
Met
￿
Lys Ser
￿
Leu Asx-Gly Asx Glx Lys Asx Phe
25
￿
30
￿
35
Ser Cys Ala Thr Ser Gly PheThr Phe Ser Asx PheTyrMet Glx Trp
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MOLARITY OF INHIBITOR
FAG. 3. Binding specificity of CBPC 2 . Inhibition of precipitation of pneumococcal C
polysaccharide by phosphorylcholine (PC), glycerophosphorylcholine (GPC), acetylcholine
(AC), and choline (C).
TABLE 11
Binding Specificity of Myeloma Proteins that Bind Phosphorylcholine
613
* 1,o = m molar concentration of hapten which gives 50% inhibition of binding of
11211)PnC to
myeloma protein.
$ Relative specificity = (molarity of GPC, AC or C at LOAmolarity of PC at I..) .
§ Numbers in parentheses are values reported by Leon and Young (4) .
Tumor
Iso* Relative specificity$
proteins
PC GPC AC C GPC/PC AC/PC C/PC
TEPC 15 0.016 0.17 4.8 7.0 10.3(11)§ 296(380) 427(550)
CBPC 2 0.010 0.082 3.0 5.2 8.2 300 520
MOPC 167 0.032 0.041 0.30 0.35 1 .3(0.8) 9.6(10) 1100)
McPC 603 0.021 0.183 18.2 19.5 8.9(10) 885(1,000) 950(870)614
￿
PHOSPHORYLCHOLINE-BINDING I9A MYELOMA PROTEIN
Idiotypic Determinants on CBPC 2 Protein .
￿
Work from theselaboratories has
shown that H8 and T15 share two different idiotypic determinants that are not
found on M511, M167, or M603 . One of these determinants, (T15), detected by
an antiserum produced in A or AL mice, is not modified by PC binding and
therefore appears to lie outside the combining site (19, 22) . In contrast, the other
determinant(s), (H88), detected by antibodies isolated from a rabbit anti-H8
serum, is in the binding site since it is completely inhibited by hapten (22) . As
shown by the hemagglutination-inhibition reaction (Table III) and by solid phase
radioimmunoassay (Fig . 4) only the H8,, determinant(s) was present on CBPC 2 .
No binding of CBPC 2 by A anti-H8 occurred, even when CBPC 2 was used at
100,000 times the effective concentration ofT15. In contrast, at a concentration
of 20 ng/ml, CBPC 2 inhibited the binding of R2 anti-H8,, to T15-SRBC to a
TABLE III
Idiotypic Specificities of PC-Binding Myelorna Proteins
* Mean determined from three separate experiments . Data represent the concentration of protein
giving complete inhibition of the reaction between H8-coated sheep erythrocytes and the rabbit (R2
anti-H88) or mouse (A/J anti-H8) idiotypic antibody .
degree comparable to that obtained with T15 andH8 . This is expressed in quanti-
tative terms by theTBA shown in Fig . 4 . On a weight basis CBPC 2 and T15 give
comparable inhibition of binding which suggests that the determinants in their
combining sites are idiotypically very similar, if not identical.
Discussion
The present studies demonstrate that a PC-binding myeloma protein, CBPC 2,
whose heavy chain is of C57BL/ka (a') origin, possesses variable region structural
and functional characteristics that are similar to those of a group ofPC-binding
myeloma proteins (S63-T15) ofBALB/c (a') origin . This conclusion is based on a
variety of criteria including antibody binding specificity, amino-terminal heavy
and light chain sequences, light chain mobility and binding site antigenic
determinants . This protein, however, is distinguished from the myeloma proteins
in the S63-T15 group since it carries C57BL/ka, instead of the BALB/c, allotype
markers and by the fact that it does not carry the nonbinding site idiotypic
determinant, T15 .
Immunoglobulin
HI titer*
R2 anti-H8. AM anti-H8
mg/ml mg/ml
BALB/c NMG >2 >2
CBPC 2 0.000020 2
HOPC 8 0.000040 0.000080
TEPC 15 0.000020 0.000020
MOPC 167 >2 >2
MOPC 511 >2 >2
McPC 603 >2 >2J. L. CLAFLIN, S. RUDIKOFF, M. POTTER, AND J . M. DAVIE
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FIG. 4.
￿
Idiotypic similarity of H8, determinant in T15 and CBPC 2. Inhibition of binding of
['I1H8 to anti-H8,-coated tubes.
The possession of the C57BL/ka (C H) heavy chain allotype suggests that the
V14 heavy chain of CBPC 2 is of C57BL/ka origin. This is supported by the fact
(20, 39) that the congenic strain CB-20 has other V H genes of C57BL/ka origin
and by the finding that the heavy chain sequence of CBPC 2 contains amino
acids in at least two positions (14 and 16) which are not found in any of 29
BALB/c myeloma proteins (see 40). Thus, it seems probable that the heavy chain
of CBPC 2 was derived intact from genetic information provided by the
C57BL/ka mouse. The origin of the light chain of CBPC 2 cannot be determined
at present since no light chain allotypes on mouse kappa chains have been
defined. Furthermore, the VL IB-peptide marker described by Edelman and
Gottlieb (41) is not found in either BALB/c or C57BL/ka mice . While there is no
a priori reason why the same light chain may not be expressed in more than one
strain of mice, it is equally likely that the CBPC 2 light chain is derived from the
BALB/c genome since the CB-20 strain was selected for allotype, and heavy and
light chain genes are not linked.
The observation that CBPC 2 possesses the H88 determinant and the same
binding specificity as T15 supports the idea that these two proteins have the
same structure in the combining site. However, CBPC 2 differs structurally from
T15 in some portion of the variable region, since it lacks the nonbinding site T15
idiotype . The location of this antigenic determinant will have to await further
experimental analysis. It is pertinent to note, however, that the hypervariable
loops of one of the PC-binding proteins, M603, are gathered together to form a
cleft which is much more extensive than that occupied with PC binding (42).
Secondly, the second hypervariable region of the light chain of M603 (42) and
also of the human myeloma protein, New, (43) is removed from the binding site
and is accessible from the outside. If this region in T15 varied from that in CBPC
2, it would be a candidate for the T15 idiotype. However, the possibility that
idiotype markers exist outside hypervariable regions still appears possible. In this
regard, positions 14 and 16 of theVH in the M603 are on the exterior surface of the616
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molecule and the interchanges found at these positions in CBPC 2 could
conceivably be nonbinding site determinants .
Recent studies (3-15) of groups of myeloma proteins have indicated a striking
correlation between binding specificity, cross-idiotypic determinants and amino-
terminal sequences of either the heavy chain and/or light chain . Proteins that
bind /3(1 - 6)-D-galactan are especially intriguing since they show similar
sequences in both their heavy and light chains (10, 12, 13) . Perhaps the most
pertinent to the present study, since they arose in genetically different individu-
als, are the human monoclonal cold agglutinins and antigamma globulins
studied by Kunkel, Capra, and their colleagues (44, 45) . Though no data on
heavy chain structure have been presented, amino acid sequence analysis of the
light chains from 6 of 10 cold agglutinins showed minimal differences among
them (46) . Likewise, antigamma globulins selected for similarity in shared
idiotypic determinants exhibit remarkable structural similarities in either their
light or their heavy chains (47) . However, no two proteins appear to be
completely identical in either structure or in individual antigenic specificity .
Thus, CBPC 2 and those in the S63-T15 group of PC-binding myeloma
proteins, at present, present a unique finding among myeloma proteins derived
from the mouse or the human . Though structural differences exist between
CBPC 2 and S63-T15, these relate to either allotypic characteristics in the CH
region or to a variable region(s) difference outside the combining site . No
detectable differences have been found in the combining site, which indicates
that this portion of the molecule has been preserved in two mouse strains that
exhibit considerable differences in their genetic make-up . In this regard, it has
been shown previously that both C57BL/6 and BALB/c, as well as all mouse
strains tested, produce anti-PC antibodies which show the same specificity (23)
and binding site antigenic determinants (19) as those of T15 and CBPC' 2 . If
indeed sequence analysis verifies the conservation of this binding site in Mus
musculus, this family of immunoglobulins will offer an excellent opportunity to
study variable region diversity as well as permit analysis of structure-function-
idiotype relationships .
Summary
An IgA phosphorylcholine (PC)-binding myeloma protein with IgCH allotypic
determinants different from those of BALB/c mice is characterized . The
myeloma, CBPC 2, was induced in the CB-20 strain of mice which is congenic to
BALB/c but differs from it by carrying the A'S allotypic determinant of
C57BL/ka mice . Sequence analysis of the CBPC 2 light chain through the first
hypervariable region, as well as isoelectric point analysis, show that this chain is
indistinguishable from that of T15, a PC-binding myeloma protein of BALB/c
origin . The heavy chains of CBPC 2 and T15 differ by only two amino acids
(positions 14 and 16) through the first hypervariable region . As measured by
inhibition of precipitation, both CBPC 2 and T15 have the same specificity for
PC, glycerophosphorylcholine, acetylcholine, and choline . In addition, CBPC 2
possesses the binding site-associated idiotypic determinant which is present on
T15 . However, like normal or induced C57BL/6 anti-PC antibody, it does not
possess the nonbinding site idiotypic determinant.J . L. CLAFLIN, S. RUDIKOFF, M. POTTER, AND J. M . DAVIE
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Receiued for publication 28 October 1974 .
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